• Publications
  • Influence
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology
2D : two-dimensional 99mTc-DPD : 99mTechnetium-3,3-diphosphono- 1,2-propanodi-carboxylic acid ACE : angiotensin-converting enzyme AF : atrial fibrillation AL : amyloid light chain AR : aorticExpand
  • 1,820
  • 150
[2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death].
Authors/Task Force Members: Silvia G. Priori* (Chairperson) (Italy), Carina Blomström-Lundqvist* (Co-chairperson) (Sweden), Andrea Mazzanti† (Italy), Nico Blom (The Netherlands), Martin BorggrefeExpand
  • 1,700
  • 98
Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial
In this position statement of the ESC Working Group on Myocardial and Pericardial Diseases an expert consensus group reviews the current knowledge on clinical presentation, diagnosis and treatment ofExpand
  • 962
  • 88
2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in
2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy : The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed inExpand
  • 1,854
  • 64
Sudden death in hypertrophic cardiomyopathy: identification of high risk patients.
OBJECTIVES We sought to identify patients with hypertrophic cardiomyopathy (HCM) at high risk of sudden death (SD). BACKGROUND Relatively low mortality rates in HCM make conventional analysis ofExpand
  • 830
  • 35
Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease.
CONTEXT Plasma levels of C-reactive protein (CRP) are independently associated with risk of coronary heart disease, but whether CRP is causally associated with coronary heart disease or merely aExpand
  • 538
  • 34
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008
Guidelines and Expert Consensus Documents summarize and evaluate all currently available evidence on a particular issue with the aim of assisting physicians and other healthcare providers inExpand
  • 2,235
  • 33
Equilibrium Contrast Cardiovascular Magnetic Resonance for the Measurement of Diffuse Myocardial Fibrosis: Preliminary Validation in Humans
Background— Diffuse myocardial fibrosis is a final end point in most cardiac diseases. It is missed by the cardiovascular magnetic resonance (CMR) late gadolinium enhancement technique. Currently,Expand
  • 689
  • 30
Mutations in Cypher/ZASP in patients with dilated cardiomyopathy and left ventricular non-compaction.
OBJECTIVES We evaluated the role of Cypher/ZASP in the pathogenesis of dilated cardiomyopathy (DCM) with or without isolated non-compaction of the left ventricular myocardium (INLVM). BACKGROUNDExpand
  • 483
  • 25
Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy.
OBJECTIVES We investigated the significance of fibrosis detected by late gadolinium enhancement cardiovascular magnetic resonance for the prediction of major clinical events in hypertrophicExpand
  • 613
  • 23